PLAY LIST from the beginning ENHERTU Business Briefing(1) Forward-Looking Statements 5-Year Business Plan (FY2021-FY2025) for Sustainable Growth Goal and Strategic Pillars for the 5-Year Business Plan (FY2021-FY2025) Major Achievements in FY2022 ENHERTU Business Briefing(2) Ken Keller Building Momentum Daiichi Sankyo OBU Leadership Roadmap to Transforming HER2 Targetable Cancers Obtained 4 New Indications in US & EU in 2022 ENHERTU Has Quickly Become the New 2L HER2+ MBC Standard of Care in the U.S. ENHERTU is the New 2L HER2+ Gastric Care Standard of Care in the U.S. ENHERTU Has Transformed the Treatment Landscape for MBC and is the New Standard of Care for HER2 low patients ENHERTU is the 2L Standard of Care in HER2 Mutant Lung Cancer In all EU Markets where ENHERTU Became Available for 2L HER2+ mBCPatients,Treatment Initiation Grew Rapidly After Launch Global Net Sales have Exceeded 60 Bn JPY Per Quarter Utilization in HER2+ mBC and HER2 low Patients in the US are the Key Drivers of ENHERTU Growth Success Can Be Attributed to Four Key Success Factors Key 3: Presentation + Publication + Guidelines Awareness and Education Efforts Have Resulted in Growing Confidence in Identifying and Managing ILD Clinical Trial Experience With ILD Enhanced ILD Education & Management Has an Impact The Oncology Community Quickly Embraced The Need to Identify Their HER2 Low Patients Achievements in FY 2022 2023 Growth Drivers # 1 Growth Opportunity: ENHERTU has Demonstrated Standard of Care Changing Benefit ~70% of mBC Patients Development Plan Expands ENHERTU Opportunity To Earlier Stage Disease (1) Development Plan Expands ENHERTU Opportunity To Earlier Stage Disease (2) Daiichi Sankyo Aims to Establish and Expand DXd-ADCs as New Treatment Options in Lung Cancer Transforming Treatment and Outcomes for Patients On Track to Transforming HER2 Targetable Cancers @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 Q&A 8 Sunao Manabe President and CEO Ken Keller Global Head, Oncology Business President & CEO, Daiichi Sankyo, Inc.
